论文部分内容阅读
Regorafenib significantly prolongs overall survival in patients with metastatic colorectal cancer(mCRC),but the overall clinical efficacy of regorafenib remains quite limited.Combination chemotherapy is a potentially promising approach to enhance anticancer activity,overcome drug resistance,and improve disease-free and overall survival.